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Articles
Genetic sequencing for surveillance of drug resistance in 
tuberculosis in highly endemic countries: a multi-country 
population-based surveillance study
Matteo Zignol*, Andrea Maurizio Cabibbe*, Anna S Dean*, Philippe Glaziou, Natavan Alikhanova, Cecilia Ama, Sönke Andres, Anna Barbova, 
Angeli Borbe-Reyes, Daniel P Chin, Daniela Maria Cirillo, Charlotte Colvin, Andrei Dadu, Andries Dreyer, Michèle Driesen, Christopher Gilpin, 
Rumina Hasan, Zahra Hasan, Sven Hoffner, Alamdar Hussain, Nazir Ismail, S M Mostofa Kamal, Faisal Masood Khanzada, Michael Kimerling, 
Thomas Andreas Kohl, Mikael Mansjö, Paolo Miotto, Ya Diul Mukadi, Lindiwe Mvusi, Stefan Niemann, Shaheed V Omar, Leen Rigouts, Marco Schito, 
Ivita Sela, Mehriban Seyfaddinova, Girts Skenders, Alena Skrahina, Sabira Tahseen, William A Wells, Alexander Zhurilo, Karin Weyer, Katherine Floyd, 
Mario C Raviglione
Summary
Background In many countries, regular monitoring of the emergence of resistance to anti-tuberculosis drugs is 
hampered by the limitations of phenotypic testing for drug susceptibility. We therefore evaluated the use of genetic 
sequencing for surveillance of drug resistance in tuberculosis.
Methods Population-level surveys were done in hospitals and clinics in seven countries (Azerbaijan, Bangladesh, 
Belarus, Pakistan, Philippines, South Africa, and Ukraine) to evaluate the use of genetic sequencing to estimate the 
resistance of Mycobacterium tuberculosis isolates to rifampicin, isoniazid, ofloxacin, moxifloxacin, pyrazinamide, 
kanamycin, amikacin, and capreomycin. For each drug, we assessed the accuracy of genetic sequencing by a 
comparison of the adjusted prevalence of resistance, measured by genetic sequencing, with the true prevalence of 
resistance, determined by phenotypic testing.
Findings Isolates were taken from 7094 patients with tuberculosis who were enrolled in the study between November, 
2009, and May, 2014. In all tuberculosis cases, the overall pooled sensitivity values for predicting resistance by genetic 
sequencing were 91% (95% CI 87–94) for rpoB (rifampicin resistance), 86% (74–93) for katG, inhA, and fabG promoter 
combined (isoniazid resistance), 54% (39–68) for pncA (pyrazinamide resistance), 85% (77–91) for gyrA and gyrB 
combined (ofloxacin resistance), and 88% (81–92) for gyrA and gyrB combined (moxifloxacin resistance). For nearly all 
drugs and in most settings, there was a large overlap in the estimated prevalence of drug resistance by genetic 
sequencing and the estimated prevalence by phenotypic testing.
Interpretation Genetic sequencing can be a valuable tool for surveillance of drug resistance, providing new 
opportunities to monitor drug resistance in tuberculosis in resource-poor countries. Before its widespread adoption 
for surveillance purposes, there is a need to standardise DNA extraction methods, recording and reporting 
nomenclature, and data interpretation.
Funding Bill & Melinda Gates Foundation, United States Agency for International Development, Global Alliance for 
Tuberculosis Drug Development.
Copyright © 2018 World Health Organization; licensee Elsevier. This is an Open Access article published under the 
CC BY 3.0 IGO license, which permits unrestricted use, distribution, and reproduction in any medium, provided the 
original work is properly cited. In any use of this article, there should be no suggestion that WHO endorses any 
specific organisation, products or services. The use of the WHO logo is not permitted. This notice should be preserved 
along with the article’s original URL.
Introduction
Antimicrobial resistance represents a threat to global 
health and security and challenges the progress made over 
the past two decades to combat tuberculosis.1 In 2016, 
WHO estimated that there were 10·4 million incident 
cases of tuberculosis.2 Furthermore, about 600 000 cases 
of multidrug-resistant tuberculosis or of rifampicin-
resistant disease were estimated to have emerged in the 
same year.2 Surveillance of drug resistance, which has 
both public and individual health consequences, is 
recognised to be a crucial component of tuberculosis 
control programmes worldwide. Surveillance data can be 
used to estimate disease burden, plan diagnostic and 
treatment services, monitor the effectiveness of 
tuberculosis control interventions, design effective 
standard treatment regimens and, if systematically 
undertaken, allow individually tailored patient care.
Global surveillance of resistance to anti-tuberculosis 
drugs, which was launched in 1994, is the oldest and 
largest global surveillance project of antimicrobial 
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resistance.3 In most countries with a high burden of 
tuberculosis, there is inadequate capacity for routine 
testing of all patients for resistance to drugs. In these 
settings, the extent of drug resistance is estimated through 
periodic epidemiological surveys, which have largely 
relied on conventional culture and drug susceptibility 
testing by use of phenotypic methods. These surveys have 
important limitations, including the need for timely 
refrigerated transportation to preserve the bacterial 
viability of samples and minimise contami nation, 
suboptimal reproducibility of tests, a long turnaround for 
results, a requirement for effective biosafety precautions 
in the operating laboratories, and high workloads for the 
reference laboratories. These factors make it difficult to 
repeat surveys at regular intervals.3
Implementation of routine diagnostic testing for drug 
susceptibility, which is recommended by WHO as part of 
their End TB Strategy, remains insufficient. In 2016, 
global surveillance data showed that only 33% of new 
patients and 61% of patients who were previously treated 
for tuberculosis had access to drug susceptibility testing 
at the time of diagnosis.2 Although the rollout of rapid 
molecular diagnostics, particularly GeneXpert MTB/RIF 
(Cepheid, Sunnyvale, CA, USA), is starting to increase 
access to susceptibility testing for rifampicin resistance, 
much greater efforts are needed to meet the WHO target 
of universal drug susceptibility testing.4
Considering the slow growth rate of Mycobacterium 
tuberculosis complex strains, molecular-based testing 
could be the only way to obtain rapid test results regarding 
drug susceptibility for many patients. There is therefore 
an urgent need for rapid and easy-to-perform molecular 
tests of drug susceptibility for a wide range of anti-
tuberculosis drugs.5 Additionally, the distribution of such 
tests requires a clear set of criteria to interpret molecular 
test results, which should be based on an understanding 
of the association between genotypic markers of 
resistance, phenotypic test results, and patient outcomes. 
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Research in context
Evidence before this study
Surveillance of resistance to anti-tuberculosis drugs is needed to 
estimate disease burden, plan diagnostic and treatment services, 
monitor the effectiveness of tuberculosis control interventions, 
design effective standard treatment regimens and, ultimately, 
allow the most appropriate, individually tailored patient care. 
We searched MEDLINE for articles published between Jan 1, 1966, 
and Sept 20, 2017, and Embase for articles published between 
Jan 1, 1980, and Sept 20, 2017. To find articles about the use of 
genetic sequencing for surveillance of drug resistance in 
tuberculosis, we used the search terms “tuberculosis”, “drug 
resistance”, “surveillance”, and “genome sequencing” to find 
publications in English, French, or Spanish. In most countries with 
a high burden of tuberculosis, there is insufficient capacity to 
routinely test all patients for resistance to anti-tuberculosis drugs. 
In these settings, the burden of drug-resistant tuberculosis is 
estimated through periodic epidemiological surveys. For more 
than 20 years, these surveys have relied on conventional culture 
and drug susceptibility testing by use of phenotypic methods. 
These methods have crucial limitations, including the need to 
preserve bacterial viability of samples, suboptimal reproducibility 
of tests, discordant testing results between assays, and the 
requirement for effective biosafety. All these factors make it 
difficult to repeat surveys at regular intervals, particularly in 
resource-poor countries. Genome sequencing is a high-
throughput technology that is mainly used in research settings 
and for surveillance purposes in high-income countries. To the 
best of our knowledge, genome sequencing has never been 
evaluated as a method for surveillance of drug resistance in 
tuberculosis in resource-poor countries. 
Added value of this study
Our Article presents the results of the first ever 
population-based surveys to investigate the use of genome 
sequencing for surveillance of the resistance of Mycobacterium 
tuberculosis to key anti-tuberculosis drugs (rifampicin, 
isoniazid, ofloxacin, moxifloxacin, pyrazinamide, kanamycin, 
amikacin, and capreomycin) in resource-limited countries. 
Although most other genome sequencing studies focus on 
patient groups that are at risk of drug resistance, we present 
data from patients with different risks of drug resistance, 
including patients who have recently been diagnosed and 
those who have already been treated for tuberculosis across 
different epidemiological settings. Our work offers insights 
into the feasibility of introducing high-throughput genome 
sequencing technology to replace conventional phenotypic 
testing for surveillance of drug resistance in tuberculosis.
Implications of the available evidence
Our results have implications for the future surveillance of 
drug resistance in tuberculosis and encourage the use of 
genome sequencing for broader surveillance of antimicrobial 
resistance. For drugs with suboptimal sensitivity of genome 
sequencing compared with phenotypic testing in the general 
patient population, the true prevalence of drug resistance can 
be determined using a relatively simple statistical adjustment. 
Our Article shows that genome sequencing is a valuable tool 
for surveillance of drug resistance in resource-poor settings 
and could potentially replace phenotypic testing in drug 
resistance surveys. Ultimately, these findings could allow the 
establishment of a comprehensive continuous surveillance 
system for drug resistance, even in settings with limited 
laboratory capacity. The findings of this study can also be 
used to guide the development and introduction of new 
diagnostic technologies in different geographical areas and 
patient groups and contribute to overall knowledge of the 
role of genotypic markers in conferring resistance to 
anti-tuberculosis drugs.
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Previous studies6,7 have summarised current know-
ledge about the correlation between genotypic markers 
and phenotypic test results. An important limitation of 
current evidence is that data are generally restricted to 
patients with a high risk of drug resistance who have 
already received treatment for tuberculosis. There is 
little evidence for a correlation between genotypic 
markers and phenotypic test results in the context of 
population-based surveillance, particularly among newly 
diagnosed patients with no known pre-existing risk of 
drug resistance. Such data are crucial for predicting the 
accuracy of new molecular tests to accurately diagnose 
drug resistance in patient groups with different 
prevalence of resistance, different pre-existing risks 
(such as in patients who have been treated several 
times), or both.5 Additionally, data on the use of genetic 
sequencing for surveillance of anti-tuberculosis drug 
resistance and tuberculosis outbreak investigations are 
primarily from industrialised countries.8 Data from 
resource-limited settings remain scarce.
We present results from a unique population-based 
surveillance study across seven resource-limited countries 
with a high burden of tuberculosis. The efficacy of genetic 
sequencing to estimate the extent of resistance of 
M tuberculosis isolates to the major first-line and second-
line anti-tuberculosis drugs (namely, rifampicin, isoniazid, 
ofloxacin, moxifloxacin, pyrazinamide, kanamycin, ami-
kacin, and capreomycin) was investigated. 
Methods
Study design and participants
Between November, 2009, and May, 2014, population-
based surveys to measure anti-tuberculosis drug resistance 
of M tuberculosis isolates were done in hospitals and 
clinics in Azerbaijan,9 Bangladesh,10 Belarus (Minsk),11 
Pakistan,12 Philippines,13 South Africa (Gauteng and 
Kwazulu Natal provinces),14 and Ukraine.15 Details on the 
design of these surveys are provided elsewhere.16 All 
patients with pulmonary tuberculosis, both newly 
diagnosed and previously treated, who presented to the 
study sites were eligible for enrolment. Site selection was 
done by cluster sampling or by inclusion of all diagnostic 
facilities in the country. The results of each study are 
described in the individual country reports.9–15,17 Each 
study obtained ethical approval and written informed 
consent from patients. 
Procedures
Strains of M tuberculosis were isolated from sputum 
samples in either Löwenstein-Jensen media or a 
BACTEC MGIT 960 liquid culture system (Becton 
Dickinson, Franklin Lakes, NJ, USA). The laboratory 
methods used in each country and additional details 
about methods are provided in the appendix. Methods 
were standardised and all laboratories successfully 
passed proficiency testing before survey initiation. The 
number of isolates that underwent phenotypic 
susceptibility testing varied between drugs, as reported 
in the results section. Phenotypic susceptibility testing 
involved growing mycobacteria in the presence of 
antibiotics; if a colony formed, the mycobacteria were 
deemed to be resistant.
Genetic sequencing data were obtained either through 
whole-genome sequencing or targeted gene sequencing of 
the relevant genomic regions of rpoB for rifampicin, katG, 
inhA, and fabG promoter for isoniazid, pncA for 
pyrazinamide, and gyrA and gyrB for the fluoro quinolones18 
(ofloxacin and moxifloxacin) by use of Sanger technology 
(Thermo Fisher Scientific, Waltham, MA, USA). Multi- 
drug-resistant tuberculosis was defined as resistance to at 
least rifampicin and isoniazid, and extensively drug-
resistant tuberculosis was defined as multidrug-resistant 
tuberculosis with additional resis tance to at least one 
fluoroquinolone and one second-line injectable drug 
(kanamycin, amikacin, or capreomycin). For whole-
genome sequencing of isolates, either Illumina technology 
(Illumina, San Diego, CA, USA) or Ion Torrent technology 
(Thermo Fisher Scientific) were used. The appendix 
presents the sequencing methods used in each country. 
Details on DNA extraction, sequencing methods, and 
primers used for Sanger sequencing are provided in the 
appendix. Whole-genome sequencing data were submitted 
to the Sequence Read Archive of the National Center for 
Biotechnology Information as recalibrated BAM files 
(accession number SRP128089). The interpretation of 
mutations in rpoB, katG, inhA, fabG promoter, pncA, gyrA, 
gyrB, rrs, and eis genes was done with a standardised 
approach for grading mutations in M tuberculosis in terms 
of their association with drug resistance.6 By this approach, 
the assessor classified the level of confidence that a 
given mutation was associated with resistance as either 
“high confidence for association with resistance”, 
“moderate confidence for association with resistance”, 
“minimal confidence for association with resistance”, “no 
association with resistance”, or “indeter minate” (appendix).
The average cost of doing genetic sequencing in the 
study was calculated and compared with the average cost 
of first-line and second-line phenotypic drug 
susceptibility testing.
Statistical analysis
The accuracy of genetic sequencing compared with 
phenotypic test results was assessed for the following 
genes: rpoB for rifampicin; katG, inhA, and fabG promoter 
for isoniazid; pncA for pyrazinamide; gyrA and gyrB for 
ofloxacin and moxifloxacin; rrs and eis for kanamycin; and 
rrs for amikacin and capreomycin. Pooled distributions 
for the sensitivity and specificity of the tests based on the 
genotypic method were obtained using random effects 
modelling after logistic transformation and use of a 
restricted maximum likelihood estimator.
Mutations classified in the high confidence, moderate 
confidence, or minimal confidence categories6 were 
considered to be conferring true resistance, even if the 
See Online for appendix
For the Sequence Read Archive 
see https://www.ncbi.nlm.nih.
gov/sra
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phenotypic testing showed susceptibility. For these cases, 
it was assumed that any phenotypic test results that 
indicated susceptibility were false negatives. The 
specificity of sequencing was thus set at 100%. 
Throughout this Article, when reference is made to the 
true prevalence of resistance as determined using 
phenotypic testing, this adjustment is accounted for. 
Where θ denotes the apparent prevalence of drug 
resistance, measured by use of genomic sequencing, and 
φ denotes the bias-corrected (true) prevalence, determined 
by use of phenotypic testing, φ is expressed in terms of θ, 
sensitivity (se), and specificity (sp), as the formula:
Uncertainty about se and sp and uncertainty around θ 
(due to sampling) were propagated. Uncertainty was 
propagated using a Bayesian model, which was 
implemented in JAGS 4.3.0.19 To set up the model, it was 
assumed that se and sp followed a beta distribution. 
Parameters were obtained by use of the method of 
moments.20 An uninformative prior was set at φ. The 
likelihood function was obtained by solving this equation 
for θ, using sp set to 1, and pooled sp values separately in 
the equation:
The conditional probability distribution of φ was 
proportional to the product of the likelihood and the 
prior,
from which summary statistics were extracted.
Role of the funding source
DPC is an employee of the Bill & Melinda Gates 
Foundation, which co-funded the study. CC, YDM, and 
WAW are employees of the United States Agency for 
International Development, which also co-funded the 
study. These authors were acting as subject matter 
experts rather than agency representatives, and did not 
have veto power over any study decision. The 
corresponding author had full access to all the data in the 
study and had final responsibility for the decision to 
submit for publication.
Results
Of 7094 patients enrolled in the study, 751 (11%) were 
from Azerbaijan, 949 (13%) from Bangladesh, 197 (3%) 
from Belarus, 1461 (21%) from Pakistan, 1017 (14%) from 
the Philippines, 1578 (22%) from South Africa, and 
1141 (16%) from Ukraine. Among all patients enrolled, 
5611 (79%) were new tuberculosis patients, 1278 (18%) 
were previously treated, and the remaining 205 (3%) had 
an unknown treatment history for tuberculosis. Of the 
7094 patients, 6124 (86%) had rifampicin-susceptible 
tuberculosis and 970 (14%) had rifampicin-resistant 
tuberculosis. The number of patients with available data 
for both genotypic and phenotypic testing of M tuberculosis 
complex isolates varied between drugs, from 7010 for 
rifampicin to 623 for kanamycin (table). Data on 
resistance to injectable drugs (kanamycin, amikacin, and 
capreomycin), and on pyra zinamide resistance in 
Ukraine, were only available for patients with rifampicin-
resistant tuberculosis. Data on the quality of sequencing 
results are reported in the appendix. The overall pooled 
sensitivity values for genetic sequencing among all 
tuberculosis cases were 91% (95% CI 87–94) for rpoB 
(rifampicin resistance), 86% (74–93) for katG, inhA, and 
fabG promoter combined (isoniazid resistance), 85% 
(77–91) for gyrA and gyrB combined (ofloxacin resistance), 
and 88% (81–92) for gyrA and gyrB combined 
(moxifloxacin resistance). The sensitivity for pncA 
(pyrazinamide) compared with MGIT 960 testing, 
adjusted for the results of the Wayne’s test, was 54% 
Loci Rifampicin-susceptible 
cases
Rifampicin-resistant 
cases
All cases
Number 
of 
isolates
Sensitivity 
(95% CI)
Number 
of 
isolates
Sensitivity 
(95% CI)
Number 
of 
isolates
Sensitivity 
(95% CI)
Rifampicin rpoB .. .. .. .. 7010 91% 
(87–94)
Isoniazid katG, 
inhA, and 
fabG 
promoter
6065 81% 
(66–90)
953 90% 
(81–95)
7018 86% 
(74–93)
Ofloxacin gyrA and 
gyrB
4244 76%  
(51–90)
866 88% 
(83–92)
5110 85% 
(77–91)
Moxifloxacin gyrA and 
gyrB
4010 81%  
(53–94)
783 91% 
(85–95)
4793 88% 
(81–92)
Pyrazinamide pncA 2310 37%  
(22–54)
683 55% 
(40–70)
2993 51% 
(35–66)
Pyrazinamide* pncA 2310 50%  
(33–67)
683 54% 
(40–68)
2993 54% 
(39–68)
Kanamycin rrs and eis .. .. 623 79% 
(58–91)
.. ..
Amikacin rrs .. .. 690 90% 
(82–95)
.. ..
Capreomycin rrs .. .. 764 81% 
(56–93)
.. ..
Multidrug-resistant NA .. .. .. .. 6986 85% 
(75–91)
Extensively 
drug-resistant
NA .. .. .. .. 756 74% 
(53–87)
*Adjusted with Wayne’s test results. 
Table: Number of clinical Mycobacterium tuberculosis isolates tested and the pooled sensitivity values of 
genetic sequencing compared with phenotypic testing, stratified by rifampicin resistance status, for 
each locus or the loci conferring resistance to the indicated drug
φ =
θ + sp – 1
se + sp – 1 
L(φ, se, sp|θ) = seφ
Prob(φ|θ) a L(φ|θ)Prob(φ)
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(39–68). Sensitivity for multidrug-resistant tuberculosis 
(resistance to rifampicin and isoniazid) was 85% (75–91), 
and sensitivity for extensively drug-resistant tuberculosis 
(multidrug-resistant tuberculosis and resistance to at 
least one fluoroquinolone and one second-line injectable 
drug) was 74% (53–87).
Sensitivity values were always higher for rifampicin-
resistant than rifampicin-susceptible isolates, but values 
were highly variable by setting and patient group 
(appendix). Variations in the sensitivity of genetic 
sequencing across geographical sites were greatest 
among rifampicin-susceptible cases for all drugs and in 
pyrazinamide-resistant isolates in all patient groups.
A detailed description of the mutations that were 
observed to be associated with resistance of each drug is 
reported in the appendix. False-negative phenotypic test 
results (ie, the isolates carrying mutations considered to 
define true resistance even in the presence of a result of 
phenotypic susceptibility) occurred in 87 (9%) of 
958 rifampicin-resistant strains, 57 (4%) of 1519 isoniazid-
resistant strains, 12 (3%) of 353 ofloxacin-resistant 
strains, 59 (19%) of 318 moxifloxacin-resistant strains, 
and nine (2%) of 479 pyrazinamide-resistant strains of all 
tuberculosis cases. Among patients with rifampicin-
resistant tuberculosis, false-negative phenotypic test 
results occurred in 16 (10%) of 163 kanamycin-resistant 
strains, five (4%) of 124 amikacin-resistant strains, and 
23 (17%) of 136 capreomycin-resistant strains.
Comparisons between the prevalence of drug resistance, 
estimated with genetic sequencing after adjustment for 
the sensitivity of sequencing, and the true prevalence of 
drug resistance, determined with pheno typic testing, were 
made for each drug (figures 1–5; appendix). There was a 
large overlap between resistance determined by genetic 
Azerbaijan
Bangladesh
Belarus
Pakistan
South Africa
Ukraine
0 25% 50% 75% 100%
Genetic sequencing
Phenotypic testing
Philippines
Figure 1: Prevalence of rifampicin resistance, estimated through genetic 
sequencing compared with phenotypic testing
Data are the adjusted prevalence of rifampicin resistance from genetic 
sequencing compared with the true prevalence of rifampicin resistance from 
phenotypic testing, shown for all tuberculosis cases. Absolute numbers are 
shown in the appendix.
Azerbaijan
Bangladesh
Belarus
Pakistan
South Africa
Ukraine
Rifampicin-resistant Rifampicin-susceptible
0 25% 50% 75% 100%0 25% 50% 75% 100%
Genetic sequencing
Phenotypic testing
Philippines
Figure 2: Prevalence of isoniazid resistance, estimated through genetic 
sequencing compared with phenotypic testing
Data are the adjusted prevalence of isoniazid resistance from genetic sequencing 
compared with the true prevalence of isoniazid resistance from phenotypic 
testing, stratified by rifampicin-resistant and rifampicin-susceptible cases. 
Absolute numbers are shown in the appendix.
Azerbaijan
Bangladesh
Belarus
Pakistan
South Africa
Ukraine
Rifampicin-resistant Rifampicin-susceptible
Genetic sequencing
Phenotypic testing
Azerbaijan
Bangladesh
Belarus
Pakistan
South Africa
Ukraine
0 25% 50% 75% 100%0 25% 50% 75% 100%
A
B
Figure 3: Prevalence of fluoroquinolone resistance, estimated through 
genetic sequencing compared with phenotypic testing
Data are the adjusted prevalence of fluoroquinolone resistance from genetic 
sequencing compared with the true prevalence of fluoroquinolone resistance 
from phenotypic testing, stratified by (A) ofloxacin and (B) moxifloxacin 
resistance and rifampicin-resistant and rifampicin-susceptible cases. 
Absolute numbers are shown in the appendix.
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sequencing and the true prevalence of drug resistance. We 
stratified results into rifampicin-resistant and rifampicin-
susceptible tuber culosis for most drugs except for the 
injectable drugs, because data regarding resistance to these 
drugs were only available for rifampicin-resistant cases.
The average cost of genome sequencing was US$150 
per sample. Drug susceptibility testing was done in two 
rounds, first with first-line drugs and then 
with second-line drugs. The average cost of conventional 
drug susceptibility testing to rifampicin, isoniazid, 
ofloxacin, moxifloxacin, pyra zinamide, kanamycin, 
amikacin, and capreomycin was $230. These costs 
included the cost of kits, reagents, and staff time.
Discussion
We have presented the results of a surveillance project of 
more than 7000 patients across several countries to assess 
the accuracy of genetic sequencing in determining the 
prevalence of resistance to the most commonly used first-
line and second-line anti-tuberculosis drugs when 
compared with phenotypic testing. We found that genetic 
sequencing can be a valuable surveillance tool to accurately 
predict drug resistance in low-income and middle-income 
countries. The value of this work is that the isolates tested 
are representative of the entire tuberculosis patient 
population in seven resource-limited countries, all of 
which are classified as having a high burden of tuberculosis 
or multidrug-resistant tuberculosis. The settings also 
differed in their risk of and extent of drug resistance. These 
patients were managed under several programmatic and 
epidemiological situations, and included patients who had 
been newly diagnosed with tuberculosis and patients who 
had previously been treated for tuberculosis.
Our results show that the accuracy of genetic 
sequencing is very good at predicting phenotypic 
resistance to rifampicin, isoniazid, the fluoroquinolones, 
and (among rifampicin-resistant cases) injectable drugs. 
These findings imply that the sensitivity values of 
sequencing compared with phenotypic testing (table) can 
be applied to sequencing results to estimate the true 
prevalence of drug resistance for surveillance purposes. 
These sensitivity values are consistent with previously 
published evidence.6,7
One of the most difficult aspects of any study on accuracy 
of a diagnostic technology is defining the gold-standard 
test to be used as comparator. Phenotypic tests are typically 
used as comparator to access the accuracy of genetic tests. 
In assessing the drug resistance of tuberculosis, the 
reliability and reproducibility of phenotypic tests are 
suboptimal for some drugs, and clinical decisions are 
often made by use of a combination of phenotypic and 
genotypic test results.21–23 In our Article, we considered the 
phenotypic test to be the gold-standard test; however, in 
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Figure 4: Prevalence of pyrazinamide resistance, estimated through genetic 
sequencing compared with phenotypic testing
Data are the adjusted prevalence of pyrazinamide resistance from genetic 
sequencing compared with the true prevalence of pyrazinamide resistance from 
phenotypic testing , stratified by rifampicin-resistant and rifampicin-susceptible 
cases. Absolute numbers are shown in the appendix.
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Figure 5: Prevalence of resistance to injectable kanamycin, amikacin, and 
capreomycin, estimated through genetic sequencing compared with 
phenotypic testing
Data are the adjusted prevalence of resistance to injectable drugs, determined 
from genetic sequencing, compared with the true prevalence of resistance to 
injectable drugs from phenotypic testing, stratified into (A) kanamycin, 
(B) amikacin, and (C) capreomycin resistance, and are shown in 
rifampicin-resistant cases. Absolute numbers are shown in the appendix.
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the event of phenotypic test results finding drug susceptibly 
alongside the presence of mutations con sidered to be 
markers of resistance, the genetic test result was assumed 
to be correct. Given the nature of this large surveillance 
project, the discrepancies between phenotypic and 
sequencing results could not be investigated by repeating 
the phenotypic test. For all discrepancies, the sequencing 
data were thoroughly reviewed. For pyrazinamide, all 
strains with discrepant results were reassessed by use of a 
third method (Wayne’s test) on the basis of the poor 
reproducibility of phenotypic tests. 
The breadth of sensitivity values observed across sites 
(appendix) reflects differences in the quality of 
phenotypic testing, random fluctuations due to test 
errors (particularly when the number of resistant cases 
was very small), and variation in the prevalence of 
resistance to rifampicin. Some of these differences could 
be partly explained by the M tuberculosis genetic back-
ground, correlation with specific drug resistance 
mutations, and clonal spread within geographical areas.
Variations in the sensitivity of sequencing, which were 
most pronounced for pyrazinamide and among 
rifampicin-susceptible cases, resulted in large uncertainty 
bounds around the estimates of prevalence by 
sequencing. To accurately monitor trends in drug 
resistance, more work should be done to improve the 
sensitivity of sequencing, particularly among rifampicin-
susceptible cases.
A larger difference between the prevalence of 
resistance as estimated by phenotypic testing and the 
adjusted prevalence by sequencing occurred when the 
sensitivity of genotypic testing was either notably higher 
or lower than in the other countries. For example, in 
Pakistan, the sensitivity of sequencing for isoniazid was 
lower than in other countries (figure 2), whereas the 
sensitivity of genotypic testing for pyrazinamide in 
Belarus (figure 4) was higher than elsewhere.
Pyrazinamide is the drug for which the ability of genetic 
sequencing to predict phenotypic resistance was most 
problematic, as shown in figure 4 by the poor overlap of 
prevalence estimates generated by phenotypic testing and 
by sequencing, particularly among rifampicin-susceptible 
strains from Belarus and Pakistan, and by large 
uncertainty bounds around the sequencing-based 
prevalence estimates. This finding was unsurprising 
because our understanding of the role of mutations in 
conferring resistance to pyrazinamide is incomplete: 
42% of all pncA mutations were unclassified in our 
dataset. Although most of these mutations have already 
been reported in the literature to be associated with 
resistance, their infrequent occurrence means that there 
is insufficient statistical power to classify them.6,22 
Additionally, the phenotypic test for pyrazinamide has 
inadequate reproducibility, making it a weak test with 
which to make comparisons.22,23
The frequency of mutations and associated phenotypic 
drug susceptibility results from our study can be used for 
genome-based predictions of resistance (appendix). To 
further improve our understanding of genotypic markers 
of resistance, phenotypic and genotypic data should be 
considered in the context of clinical outcome data, given 
the suboptimal reliability and reproducibility of phenotypic 
tests for some anti-tuberculosis drugs and uncertainty 
around the most appropriate critical concentrations.24 To 
accelerate the transition from reliance on phenotypic 
results to genotypic results for resistance prediction, it is 
crucial that genotypic, phenotypic, and outcome data be 
shared as soon as they become available.
The main purpose of surveillance is to estimate the 
burden of drug resistance and monitor its trends, to 
enable a prompt and effective public health response. 
Our findings show that genotypic methods have an 
important role in surveillance, especially given the 
limitations of conventional phenotypic methods, and 
that available molecular diagnostic tools can only detect 
resistance to a small number of drugs. Targeted gene 
sequencing or whole-genome sequencing directly on 
sputum samples would bypass the need for culture, 
standardise the approach, and accelerate the availability 
of results.25 When genetic sequencing is properly 
standardised and made economically feasible, this 
technology could be particularly impactful in countries 
with low laboratory and sample referral capacity, and 
would offer an opportunity to monitor the development 
of drug resistance more effectively during tuberculosis 
epidemics. Enabling use of gene sequencing would also 
represent a breakthrough in improving rapid surveillance 
of both drug-resistant tuberculosis and broader 
antimicrobial resistance.
The cost of genetic sequencing will be a major factor in 
determining the feasibility of introduction and the speed 
of expansion. Costs of sequencing are progressively 
decreasing and are already lower than the cost of 
phenotypic testing to first-line and second-line anti-
tuberculosis drugs in most settings.26 This trend has also 
been confirmed in our study. In the context of 
surveillance, the possibility of grouping specimens to 
genome sequence many isolates (up to 200) in one single 
run offers the potential for further cost savings and a 
reduction in laboratory workload.
Besides cost, there are several other technical chal-
lenges that need to be addressed to allow widespread use 
of genetic sequencing for surveillance of drug resistance 
in tuberculosis. DNA extraction and sample preparation 
methods need to be consistent, standardised 
nomenclature to record and report sequencing 
information must be developed, an external quality 
assurance system for genome sequencing (similar to the 
system available for phenotypic testing) should be 
established, and a standardised and common approach 
to analysis must be defined.3,27–29 To support the expansion 
of the use of sequencing technologies in low-income and 
middle-income countries, molecular biology and 
bioinformatics skills should be developed locally and 
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supplemented with continuous mentoring from 
supranational reference laboratories.
Although constraints for the expansion of genetic 
sequencing exist, the value of whole genome sequencing 
data is enormous for any national tuberculosis control 
programme. Data can be re-analysed at a later stage to 
investigate newly discovered resistance-associated loci, to 
predict resistance to new drugs, and to inform 
development of more tailored molecular diagnostics as 
soon as knowledge on the genetic marker of resistance 
becomes available.
Our study has some limitations. First, excepting isolates 
with graded mutations, which were all assumed to be 
phenotypically resistant as previously described,6 we 
considered phenotypic drug susceptibility testing to be the 
gold-standard test, and we treated this test as a comparator 
for genetic sequencing. However, there is evidence that 
phenotypic drug susceptibility testing might not always be 
the most accurate test. Treatment outcome data should be 
used to guide interpretation of genotypic and phenotypic 
testing results21 and, unfortunately, these data were not 
available in our study. Second, phenotypic testing was 
done at specific critical concentrations, as currently 
recommended by WHO,30 but more recent evidence 
suggests that some of these concentrations might need to 
be reassessed.24 Third, although only laboratory methods 
recommended by WHO were used and all laboratories 
passed proficiency testing before beginning the project, 
some variability in phenotypic results between laboratories 
and between media types could have affected outcomes. 
Fourth, different platforms were used for DNA 
sequencing, including Sanger platforms, which could 
have slightly different coverage of some genomic regions.31 
Finally, given that testing for second-line injectable drugs 
was limited to strains with rifampicin resistance, the 
number of isolates tested for kanamycin, amikacin, and 
capreomycin is not large enough to generate conclusive 
evidence.
Our work shows that genetic sequencing can be a 
valuable tool in surveillance of drug resistance, enabling 
new ways to monitor drug resistance in tuberculosis in 
low-income and middle-income countries. The findings 
of this study can also be used to guide the development 
and introduction of new diagnostic technologies, 
including genetic sequencing, in different geographical 
areas and patient groups and contribute to our knowledge 
on the role of genotypic markers in conferring resistance 
to anti-tuberculosis drugs.
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